Attacking form of epilepsy, next-generation gene therapy company raises $135 million

The company, started five years ago by Kartik Ramamoorthi and Stephanie Tagliatela, has raised $290 million and will start a clinical trial next year against Dravet Syndrome.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.